We examined the relationship between weight changes following preoperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) and weight changes from the start of medical weight management (MWM) till 12 months after bariatric surgery in patients with Type 2 diabetes in a retrospective cohort study. Forty-five patients (64.4% women, median age 49 (IQR 45-60) years) were included. The median weight loss from start of MWM until 12 months post-surgery was 17.9% (13.0%-29.3%). GLP-1 RA during MWM resulted in 5.0% (1.9%-7.7%) weight loss. Weight loss during GLP-1 RA treatment predicted weight loss from the start of MWM till 12 months post-surgery; but not post-operative weight loss following adjustment. The proportion of weight loss from start of MWM to 12 months post-surgery attributed to GLP-1 RA was negatively associated with that attributed to surgery following adjustment. In conclusion, weight change following GLP-1 RA predicted the weight loss achieved by a combination of MWM and bariatric surgery, but not weight loss induced by surgery only. Failure to lose weight following GLP-1 RA should not be considered a barrier to having bariatric surgery.
Bibliographical noteThis is the peer reviewed version of the following article: Tang T, Abbott S, CW le Roux, et al. Preoperative weight loss with glucagon‐like peptide‐1 receptor agonist treatment predicts greater weight loss achieved by the combination of medical weight management and bariatric surgery in patients with type 2 diabetes: A longitudinal analysis. Diabetes Obes Metab. 2018;20:745–748, which has been published in final form at https://doi.org/10.1111/dom.13131. This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.
- bariatric surgery
- glucagon-like peptide-1 receptor agonist
- aparoscopic adjustable gastric band
- laparoscopic sleeve gastrectomy
- Roux-en-Y gastric bypass
- type 2 diabetes mellitus
- weight loss